

23 | 03 | 2022

EAP Working Group

# Executive summary of Session 4 of the VALUE-Dx Regulatory/HTA/Payer EAP

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.





UNIVERSITÀ  
di VERONA



University Medical Center Groningen



**RAMBAM**  
Health Care Campus



**UNIVERSIDAD  
DE LA RIOJA**



**NICE** National Institute for  
Health and Care Excellence

Gesundheit Österreich  
GmbH



**ESCMID** EUROPEAN SOCIETY  
OF CLINICAL MICROBIOLOGY  
AND INFECTIOUS DISEASES



**ERS** EUROPEAN  
RESPIRATORY  
SOCIETY  
every breath counts



# Fourth EAP session

## 1.1. Meeting overview

The fourth session of the VALUE-Dx Expert Advisory Panel (EAP) was held virtually on the 23<sup>rd</sup> of March 2022. There were nine members of the EAP present.

## 1.2. Topics and themes discussed

### 1. VALUE-Dx Progress update

Progress of the PRUDENCE trial (RCT of point of care diagnostics for enhancing the quality of antibiotic prescribing for community acquired acute respiratory tract infection in ambulatory care in Europe).

2. HTA approaches and whether they differ for preventative interventions compared to clinical or therapeutic interventions
3. Whether HTAs can incorporate less tangible benefits of diagnostics such as clinician and patient confidence
4. Appropriate KPIs to capture a reduction in unnecessary antibiotic prescribing
5. Comment on outcomes used in PRUDENCE
6. Patient population that should be targeted with POC-testing in daily practice
7. Differences between countries (high vs low prescribing) in POC testing for AMR
8. The Lancet paper on the global burden of AMR
9. Presentation from guest speaker

Global alliance of diagnostics (FIND) provided an overview of the ACT-Accelerator (ACT-A) consortium that was convened to address the needs of COVID-19. Covered the innovation in molecular diagnostics, including increased POC tests, isothermal amplification technologies and new readout methods.

RCT- randomised controlled trial, HTA- health technology assessment, KPIs- key performance indicators, POC- point of care, AMR- antimicrobial resistance

